YAP1 and neoplasm: Studies have shown that YAP/TAZ activation upregulates PD-L1 expression, leading to tumor immune suppression; hence, the combination of Hippo pathway inhibitors (e.g., verteporfin) with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies) can synergistically enhance antitumor immunity (Janse van rensburg et al., 2018; Zeng and Dong, 2021; Sun et al., 2023).